Physician profile
Lisa Kim
NPI 1104169796
$2,308.72
in general payments reported to CMS, 2019-2025
18 companies · $594 in 2025
The $594 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $460 · 2023: $523 · 2024: $423 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $588.03 | 2022-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $306.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $237.58 | 2021-2024 | |
| Novo Nordisk INC | $230.59 | 2021-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $177.76 | 2021-2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $122.94 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $110.40 | 2022 | |
| Intuitive Surgical, INC. | $98.22 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $87.77 | 2024-2025 | Farxiga, Breztri |
| Gilead Sciences, INC. | $62.82 | 2021-2022 | |
| Pfizer INC. | $62.48 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.06 | 2025 | Jardiance |
| Amarin Pharma, INC. | $46.73 | 2021-2022 | |
| Dexcom, INC. | $30.45 | 2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $24.55 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.19 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.17 | 2023 | |
| Janssen Biotech, INC. | $15.93 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.